DK4140297T3 - Mus med en konstrueret immunglobulin-lambda-letkæde og anvendelser deraf - Google Patents

Mus med en konstrueret immunglobulin-lambda-letkæde og anvendelser deraf Download PDF

Info

Publication number
DK4140297T3
DK4140297T3 DK22188627.8T DK22188627T DK4140297T3 DK 4140297 T3 DK4140297 T3 DK 4140297T3 DK 22188627 T DK22188627 T DK 22188627T DK 4140297 T3 DK4140297 T3 DK 4140297T3
Authority
DK
Denmark
Prior art keywords
mice
light chain
lambda light
engineered immunoglobulin
immunoglobulin lambda
Prior art date
Application number
DK22188627.8T
Other languages
Danish (da)
English (en)
Inventor
John Mcwhirter
Andrew J Murphy
Lynn Macdonald
Chunguang Guo
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK4140297T3 publication Critical patent/DK4140297T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1264—DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK22188627.8T 2017-12-05 2018-12-04 Mus med en konstrueret immunglobulin-lambda-letkæde og anvendelser deraf DK4140297T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762594944P 2017-12-05 2017-12-05
US201762594946P 2017-12-05 2017-12-05
US201762609241P 2017-12-21 2017-12-21
US201762609251P 2017-12-21 2017-12-21
EP18821945.5A EP3720279B1 (en) 2017-12-05 2018-12-04 Mice having an engineered immunoglobulin lambda light chain and uses thereof

Publications (1)

Publication Number Publication Date
DK4140297T3 true DK4140297T3 (da) 2025-06-23

Family

ID=64734263

Family Applications (2)

Application Number Title Priority Date Filing Date
DK22188627.8T DK4140297T3 (da) 2017-12-05 2018-12-04 Mus med en konstrueret immunglobulin-lambda-letkæde og anvendelser deraf
DK18821945.5T DK3720279T3 (da) 2017-12-05 2018-12-04 Mus med et modificeret immunoglobulin-Lambda-letkæde og anvendelser deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK18821945.5T DK3720279T3 (da) 2017-12-05 2018-12-04 Mus med et modificeret immunoglobulin-Lambda-letkæde og anvendelser deraf

Country Status (24)

Country Link
US (3) US11051498B2 (enExample)
EP (3) EP3720279B1 (enExample)
JP (2) JP7430636B2 (enExample)
KR (2) KR20250022220A (enExample)
CN (2) CN116058333A (enExample)
AU (2) AU2018381316B2 (enExample)
BR (1) BR112020011184A2 (enExample)
CA (1) CA3084049A1 (enExample)
DK (2) DK4140297T3 (enExample)
ES (2) ES2928995T3 (enExample)
FI (1) FI4140297T3 (enExample)
HR (2) HRP20250920T1 (enExample)
HU (2) HUE071852T2 (enExample)
IL (2) IL274797B2 (enExample)
LT (2) LT3720279T (enExample)
MX (2) MX2020005830A (enExample)
PL (2) PL4140297T3 (enExample)
PT (2) PT4140297T (enExample)
RS (2) RS63772B1 (enExample)
SG (1) SG11202003044SA (enExample)
SI (2) SI4140297T1 (enExample)
SM (2) SMT202500277T1 (enExample)
TW (2) TW202438676A (enExample)
WO (1) WO2019113065A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
RU2580017C2 (ru) 2010-07-26 2016-04-10 Трианни, Инк. Трансгенные животные и способы применения
HRP20181866T1 (hr) 2013-02-22 2019-01-25 Regeneron Pharmaceuticals, Inc. Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
EP3720279B1 (en) 2017-12-05 2022-09-21 Regeneron Pharmaceuticals, Inc. Mice having an engineered immunoglobulin lambda light chain and uses thereof
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
BR112021016173A2 (pt) 2019-02-22 2021-11-03 Regeneron Pharma Roedor geneticamente modificado, métodos de produção de um roedor geneticamente modificado e de produção de um anticorpo anti-nav1.7, célula ou tecido isolado de roedor, linhagem celular imortalizada, embrião de roedor, construto de ácido nucleico de direcionamento, e, hibridoma
KR20220025838A (ko) * 2019-07-01 2022-03-03 트리아니, 인코포레이티드 유전자이식 포유동물 및 사용 방법
ES3027509T3 (en) * 2019-07-01 2025-06-16 Zoetis Services Llc Transgenic rodents and methods of use thereof
KR20230066386A (ko) 2020-09-11 2023-05-15 리제너론 파마슈티칼스 인코포레이티드 항원 특이적 항체의 확인 및 제조
CA3199879A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
US12371487B2 (en) 2020-12-23 2025-07-29 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
CN114763558B (zh) * 2021-01-14 2024-02-20 上海泰槿生物技术有限公司 重组基因组、非人哺乳动物细胞及其产生方法和用途
CN118511853A (zh) * 2021-03-31 2024-08-20 瑞泽恩制药公司 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
ES2301183T3 (es) * 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
CA2422155A1 (en) * 2000-08-03 2002-02-14 Wim Van Schooten Production of humanized antibodies in transgenic animals
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP3269235B1 (en) 2001-11-30 2022-01-26 Amgen Fremont Inc. Transgenic mice bearing human ig lambda light chain genes
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
NZ583799A (en) * 2007-09-12 2011-12-22 Probiodrug Ag Transgenic mice comprising a DNA transgene encoding ABeta peptide
PL3456190T3 (pl) * 2008-06-27 2022-06-06 Merus N.V. Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy
LT2346994T (lt) 2008-09-30 2022-03-10 Ablexis, Llc Knock-in pelė, skirta chimerinių antikūnų gamybai
EP2564695B1 (en) 2009-07-08 2015-04-15 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) * 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
RU2425880C2 (ru) 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
CN104404050B (zh) 2010-06-22 2018-06-08 瑞泽恩制药公司 杂交轻链小鼠
HUE047687T2 (hu) 2011-02-25 2020-05-28 Regeneron Pharma ADAM6 egér
KR102762747B1 (ko) 2011-10-17 2025-02-05 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 마우스
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US9706759B2 (en) * 2011-12-20 2017-07-18 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
EP3912465A1 (en) 2012-02-01 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
KR102266274B1 (ko) * 2012-06-12 2021-06-17 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
EP3561050B1 (en) 2013-02-20 2021-12-08 Regeneron Pharmaceuticals, Inc. Genetic modification of rats
MX369747B (es) 2013-04-16 2019-11-20 Regeneron Pharma Modificación dirigida del genoma de rata.
AU2014330922A1 (en) 2013-10-01 2016-03-03 Kymab Limited Animal models and therapeutic molecules
DK3354732T3 (da) 2014-06-23 2020-04-06 Regeneron Pharma Nukleasemedieret dna-samling
RU2734770C2 (ru) 2014-11-21 2020-10-23 Регенерон Фармасьютикалз, Инк. Способы и композиции для нацеленной генетической модификации с использованием парных гидовых рнк
RU2707137C2 (ru) 2014-12-19 2019-11-22 Регенерон Фармасьютикалз, Инк. Способы и композиции для нацеленной генетической модификации посредством одноэтапного множественного нацеливания
KR102784608B1 (ko) 2016-06-03 2025-03-27 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
EP3720279B1 (en) 2017-12-05 2022-09-21 Regeneron Pharmaceuticals, Inc. Mice having an engineered immunoglobulin lambda light chain and uses thereof

Also Published As

Publication number Publication date
IL318197A (en) 2025-03-01
KR20200093570A (ko) 2020-08-05
BR112020011184A2 (pt) 2020-11-17
CN111432635A (zh) 2020-07-17
AU2018381316B2 (en) 2025-06-26
SMT202500277T1 (it) 2025-09-12
EP3720279B1 (en) 2022-09-21
US20210345591A1 (en) 2021-11-11
RU2020118699A (ru) 2022-01-10
HRP20250920T1 (hr) 2025-09-26
PL3720279T3 (pl) 2023-01-16
MX2020005830A (es) 2020-08-20
EP4140297A1 (en) 2023-03-01
PL4140297T3 (pl) 2025-08-25
IL274797B2 (en) 2025-06-01
JP2024036440A (ja) 2024-03-15
KR20250022220A (ko) 2025-02-14
HUE071852T2 (hu) 2025-09-28
RS63772B1 (sr) 2022-12-30
MX2024004496A (es) 2024-05-08
RS67058B1 (sr) 2025-08-29
US20190223418A1 (en) 2019-07-25
HUE060608T2 (hu) 2023-03-28
TW201938019A (zh) 2019-10-01
EP3720279A1 (en) 2020-10-14
SMT202200448T1 (it) 2023-01-13
JP7430636B2 (ja) 2024-02-13
WO2019113065A1 (en) 2019-06-13
LT4140297T (lt) 2025-07-25
AU2018381316A1 (en) 2020-04-23
FI4140297T3 (fi) 2025-07-10
ES3035461T3 (en) 2025-09-03
SG11202003044SA (en) 2020-04-29
EP4596688A3 (en) 2025-11-12
PT3720279T (pt) 2022-10-06
US12356967B2 (en) 2025-07-15
CN116058333A (zh) 2023-05-05
HRP20221459T1 (hr) 2023-01-20
US20210292439A1 (en) 2021-09-23
PT4140297T (pt) 2025-07-09
EP4596688A2 (en) 2025-08-06
TW202438676A (zh) 2024-10-01
IL274797B1 (en) 2025-02-01
SI3720279T1 (sl) 2022-11-30
IL274797A (en) 2020-07-30
CN111432635B (zh) 2022-10-21
DK3720279T3 (da) 2022-10-24
ES2928995T3 (es) 2022-11-24
LT3720279T (lt) 2022-10-25
SI4140297T1 (sl) 2025-08-29
JP7765514B2 (ja) 2025-11-06
TWI827567B (zh) 2024-01-01
CA3084049A1 (en) 2019-06-13
AU2025204547A1 (en) 2025-07-10
RU2020118699A3 (enExample) 2022-04-07
EP4140297B1 (en) 2025-05-21
US11051498B2 (en) 2021-07-06
KR102760506B1 (ko) 2025-02-04
JP2021505141A (ja) 2021-02-18

Similar Documents

Publication Publication Date Title
DK4140297T3 (da) Mus med en konstrueret immunglobulin-lambda-letkæde og anvendelser deraf
DK3802608T3 (da) Anti-cd3-antistoffer og anvendelser deraf
EP3904386A4 (en) Antibody and use thereof
EP3759143A4 (en) ANTI-TIGIT ANTIBODIES AND THEIR USES
EP3740224A4 (en) ANTI-LILRB ANTIBODIES AND THEIR USES
DK3625263T3 (da) Anti-galectin- 9-antistoffer og anvendelser deraf
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
EP3802612A4 (en) Anti-b7-h3 antibody and use thereof
IL289354A (en) Anti-cd154 antibodies and uses thereof
EP3735427A4 (en) ANTI-MCT1 ANTIBODIES AND ASSOCIATED USES
EP3904382A4 (en) ANTI-IL-23P19 ANTIBODIES AND ITS USES
DK3898668T3 (da) Antistoffer der neutraliserer hepatitis b virus og anvendelser deraf
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
EP4071172A4 (en) ANTI-LILRB1 ANTIBODIES AND ITS USES
IL281297A (en) Anti-npr1 antibodies and uses thereof
EP3790586A4 (en) Anti-dll3 antibodies and uses thereof
EP4025609A4 (en) ANTI-STEAP1 ANTIBODIES AND THEIR USES
EP3962954A4 (en) ANTI-GALECTIN-9 ANTIBODIES AND THEIR USES
EP3621993A4 (en) ANTI-INTERFERON GAMMA ANTIBODIES AND THEIR USES
EP4001308A4 (en) Anti-tigit antibodies and application thereof
EP3894440A4 (en) ANTI-IL-27 ANTIBODIES AND THEIR USES
IL279790A (en) Anti-l1cam antibodies and uses thereof
EP3947462A4 (en) ANTI-GALECTIN-9 ANTIBODIES AND THEIR USES
DK3580237T3 (da) Fgf21-mimetiske antistoffer og anvendelser deraf
EP3585816A4 (en) CXCR2 ANTIBODIES AND THEIR USES